---
title: 'Funding Daily Summary: What Happened on November 16, 2026'
headline: Sofinnova closes €725 million fund for later-stage biotech
description: Seawolf raised $100 million alongside a Sanofi partnership worth up to
  $1.2 billion. Flagship committed £100 million to a London-based AI venture lab.
url: https://thebench.bio/news/funding/2026-11-16
topic: funding
date: '2026-11-16'
covers:
- '2026-11-16'
date_published: '2026-11-16T12:01:41Z'
date_modified: '2026-11-17T00:01:42Z'
tags:
- Industry
- Software
- Clinical
- Funding
sources: 7
publisher: TheBench.Bio
---

# Funding Daily Summary: What Happened on November 16, 2026

**Sofinnova closes €725 million fund for later-stage biotech**

Seawolf raised $100 million alongside a Sanofi partnership worth up to $1.2 billion. Flagship committed £100 million to a London-based AI venture lab.

## Today in brief

Sofinnova Partners closed a €725 million fund for later-stage life-sciences companies, targeting about 15 businesses, mainly in Europe. [1] [2] The fund is 63% larger than its predecessor and has already backed Hemab Therapeutics, CellCentric and Neurent Medical. [1]

Seawolf Therapeutics secured $100 million from investors including Versant Ventures, Eli Lilly, MPM BioImpact and Novartis’ venture arm, and disclosed a Sanofi partnership worth up to $1.2 billion. [3] [4] Flagship Pioneering set aside £100 million for a London lab to create AI-focused companies, with an initial team of about 50 people planned. [5] [6]

## Sofinnova targets about 15 later-stage companies with €725 million fund

Sofinnova Partners closed its second crossover fund at €725 million, 63% larger than its first, to back biopharma and medical technology companies moving through clinical development toward commercialization. [1] The firm expects to invest mainly in Europe, with selected investments in the United States and other markets, and plans to support about 15 companies. [1] [7]

Crossover II has invested in Hemab Therapeutics, CellCentric and Neurent Medical, three European companies developing treatments for bleeding and clotting disorders, cancer, and chronic rhinitis, respectively. [1] [7] Sofinnova said companies backed by its first crossover fund later raised a combined €3.4 billion. That portfolio included businesses acquired by AstraZeneca, Asahi Kasei and Inari Medical. [1]

The fund will invest in private and publicly traded companies, and Sofinnova plans to retain capital for follow-on investments, the firm said. [1] Partner Kinam Hong said European companies can face a capital shortage when they enter larger clinical trials and may need funding longer than expected, including when public markets are closed. [1]

## Seawolf raises $100 million and discloses Sanofi deal worth up to $1.2 billion

Seawolf Therapeutics raised $100 million from investors including Versant Ventures, Eli Lilly, MPM BioImpact and Novartis’ venture arm. [3] [4] The company is developing ways to deliver genetic medicines without viruses. Viral vectors can trigger antibodies that prevent repeat dosing and can cause serious side effects at high doses. [3]

Seawolf also disclosed a partnership with Sanofi valued at up to $1.2 billion. [4] Viral vectors have enabled gene delivery in several rare diseases and are being evaluated in hundreds of trials. [3]

## Also worth knowing

- Flagship Pioneering committed £100 million to open its first company-creation lab outside the United States, in London. It expects to recruit and train about 50 scientist-entrepreneurs and operators, and hopes to secure a further £500 million through partnerships. [5] [6]

## The day in numbers

- **€725 million**: Sofinnova Partners’ second crossover fund, 63% larger than its predecessor. [1]
- **$100 million**: Investment raised by Seawolf Therapeutics. [3] [4]
- **Up to $1.2 billion**: Maximum stated value of Seawolf’s partnership with Sanofi. [4]
- **£100 million**: Flagship Pioneering’s initial commitment to its London lab. [5] [6]

## Also published

- [Atlas Venture 2026 Year In Review](<https://lifescivc.com/2026/11/atlas-venture-2026-year-in-review/?utm_source=rss&utm_medium=rss&utm_campaign=atlas-venture-2026-year-in-review>), LifeSciVC

## Sources

1. [Sofinnova closes €725M fund to back Europe’s late-stage biotechs](<https://european-biotechnology.com/latest-news/sofinnova-closes-e725m-fund-to-back-europes-late-stage-biotechs/>), European Biotechnology, 2026-11-16
2. [One of Europe’s leading VCs banks a €725M ‘crossover’ fund](<https://www.biopharmadive.com/news/sofinnova-crossover-fund-ii-european-investment/874656/>), BioPharma Dive, 2026-11-16
3. [STAT+: Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues](<https://www.statnews.com/2026/11/16/versant-lilly-put-100-million-behind-new-startup-aimed-at-solving-one-of-gene-therapys-thorniest-issues/?utm_campaign=rss>), STAT Biotech, 2026-11-16
4. [Big-name investors pour $100M into DNA therapeutics developer Seawolf](<https://www.biopharmadive.com/news/seawolf-therapeutics-dna-versant-startup-financing/874465/>), BioPharma Dive, 2026-11-16
5. [Moderna creator Flagship Pioneering brings £100M AI lab to London](<https://european-biotechnology.com/latest-news/moderna-creator-flagship-pioneering-brings-100m-ai-lab-to-london/>), European Biotechnology, 2026-11-16
6. [Flagship Pioneering expands to UK with £100m AI-native lab ](<https://www.pharmaceutical-technology.com/news/flagship-pioneering-uk-expansion-100m-ai-native-lab/>), Pharmaceutical Technology, 2026-11-16
7. [Sofinnova Partners backs European life sciences sector with €725M raise](<https://www.pharmaceutical-technology.com/news/sofinnova-partners-life-sciences-crossover-ii-fund/>), Pharmaceutical Technology, 2026-11-16

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://european-biotechnology.com/latest-news/sofinnova-closes-e725m-fund-to-back-europes-late-stage-biotechs/>
[2]: <https://www.biopharmadive.com/news/sofinnova-crossover-fund-ii-european-investment/874656/>
[3]: <https://www.statnews.com/2026/11/16/versant-lilly-put-100-million-behind-new-startup-aimed-at-solving-one-of-gene-therapys-thorniest-issues/?utm_campaign=rss>
[4]: <https://www.biopharmadive.com/news/seawolf-therapeutics-dna-versant-startup-financing/874465/>
[5]: <https://european-biotechnology.com/latest-news/moderna-creator-flagship-pioneering-brings-100m-ai-lab-to-london/>
[6]: <https://www.pharmaceutical-technology.com/news/flagship-pioneering-uk-expansion-100m-ai-native-lab/>
[7]: <https://www.pharmaceutical-technology.com/news/sofinnova-partners-life-sciences-crossover-ii-fund/>
